As part of the biopharmaceutical industry’s efforts to improve health outcomes for patients in underserved communities, PhRMA member companies are identifying ways to improve clinical trial diversity and reduce barriers to participation for Black and Brown communities. As these efforts continue to take shape, our industry is developing potential best practices and key learnings that we are excited to share as part of our effort to tackle these challenges head on.
This week, the first ever industry-wide principles on clinical trial diversity took effect. Adopted by PhRMA membership in November 2020 as a new chapter in the already existing “Principles on Conduct of Clinical Trials & Communication of Clinical Trial Results,” these principles build on the industry’s commitment to earn trust and address the systemic issues that deter Black and Brown communities from participating in clinical trials, so that people who want to participate, can. These efforts can be a key part of health equity and advancing racial justice by helping address health disparities to help ensure clinical trials better reflect the people that medicines/therapeutics are intended to treat.
“We are deeply committed to creating a more diverse, equitable and inclusive culture not only within our own walls and our communities, but also across our clinical trials,” noted Jeremy Chadwick, Head Global Development Office in Takeda R&D and executive sponsor for Takeda’s internal clinical trial diversity working group. “We are proud to stand behind the PhRMA Clinical Trial Diversity Principles and have multiple initiatives underway that align with this framework.”
Here’s how some PhRMA member companies are working to enhance diversity in clinical trial participation, as part of the industry’s overall mission to help address health inequities in the United States:
“Diversity in clinical trials is so important to me personally, as well as to Takeda. We need to drive long-term sustainable change so that studies are conducted in a truly inclusive and equitable way. We established our internal working group to define our objectives and implement meaningful changes in how we conduct studies.
“Additionally, we established a Clinical Trial Diversity function within Clinical Operations, leveraged patient input to create study-essential documents with intended populations in mind, and created investigator training programs around the world, with a focus on medically underserved communities. We’re energized by these initial steps while recognizing there is much more work to be done within Takeda and across the industry.” -- Karen Correa, Head Global Clinical Operations and lead of Takeda’s clinical trial diversity working group.
-
“We are collaborating with patients, advocacy groups, regulatory agencies, health care professionals and community organizations to identify and implement solutions that will result in diverse representation while improving health equity and generating evidence to help support better patient outcomes. We aim to recruit more clinical trial investigators and external advisors from racial/ethnic minority populations to help us ensure that clinical trial participation more closely reflects the composition of the U.S. patient population.” -- Robert Baker, Vice President of Design Hub and Exploratory Medicine at Eli Lilly and Company.
-
“Ensuring diversity of volunteers in clinical trials is a matter of equity and good science. Pfizer is committed to reducing disparities and ensuring that the participants in our clinical trials reflect the demographics of the countries and communities in which we conduct our studies. We are taking many steps to deliver on this commitment. For example, using a data-driven approach, we are choosing investigative sites in communities that represent a diverse pool of potential participants, to make it easier for people living in the community to participate. Pfizer is also doing more to engage diverse health care providers and patient advocacy partners and build relationships with local organizations who are trusted voices and resources for patients.
“We are also making it easier for patients to find information about potential trials available to them, providing culturally-sensitive materials tailored to patients in multiple languages. Overcoming barriers and challenges to fair representation in clinical trials won’t happen overnight nor can it be achieved by a single company. There is much work to be done, but it is critical that we ensure equity in our clinical trials. It is the right thing to do for science, for public health and for patients who are waiting for the next breakthrough.” -- Rod MacKenzie, PhD, Chief Development Officer and Executive Vice President of Global Product Development at Pfizer Inc.
-
“Amgen stands with PhRMA and our industry partners in the critical, long-overdue initiative to increase clinical trial diversity. Taking steps to tackle this issue is not new to Amgen. Our commitment began in 2016 under the visionary leadership of ABEN (Amgen Black Employee Network). In October 2020 we launched the RISE (Representation in Clinical Research) Program. Among the steps RISE is taking are addressing how Amgen approaches its clinical trial designs, how we select our investigators and sites, and how we are engaging with external collaborators to focus on community partnerships.
“We believe that a patient-focused approach based on trust, partnership, communication, access and patient support models will make it easier for all patients to enroll in and complete our clinical trials.” -- Darryl Sleep, MD (MBBCh, FCS (SA)), Chief Medical Officer, Amgen.
-
Ultimately, diverse clinical trials can help support a better understanding of the medicines being studied. With the implementation of the principles on clinical trial diversity, the biopharmaceutical industry has voluntarily committed to continuing to work with patients, patient advocacy groups, regulatory authorities, health care practitioners, academics and policymakers to define the systematic and impactful approaches that can enhance the diversity of clinical trial participants and help reduce health care disparities.
Read a summary of the industry’s principles on clinical trial diversity.
Learn more about the PhRMA’s commitment and progress to improving health equities at PhRMA.org/Equity.
Dr Freda Lewis-Hall
During her 35-year career in medicine, Dr. Freda Lewis-Hall has been on the frontlines of health care as a clinician, researcher, and leader in the biopharmaceuticals and life sciences industries. An award-winning advocate for health equity and improved outcomes for all patients, she provides advice and consumer health information on national programs such as "Dr. Phil," and "The Doctors," and is a regular speaker making dozens of appearances a year at consumer and health care conferences.
Dr Freda Lewis-Hall
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Between hope and despair: Improving cancer outcomes
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Traditional HTA methods treat everyone like the “average” patient
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Potential gene therapies bring hope to patients with sickle cell disease
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Sharing rebates can improve access to medicines and increase health equity
PhRMA will continue to advocate for equity within our industry
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
PhRMA awards $100,000 to fund projects that address health inequalities
Observing National Minority Health Month in the age of COVID-19
PhRMA member companies share how they are improving clinical trial diversity
Health Equity
PhRMA member companies share how they are improving clinical trial diversity
PhRMA member companies share how they are improving clinical trial diversity